Punicic Acid — Hermetica Encyclopedia
Named Bioactive Compounds · Other

Punicic Acid

Moderate Evidencelipid2 PubMed Studies

Hermetica Superfood Encyclopedia

The Short Answer

Punicic acid is a conjugated linolenic acid (CLnA) isomer found predominantly in pomegranate seed oil, comprising up to 80% of its fatty acid content. It exerts biological activity primarily through modulation of MAPK/ERK signaling cascades and interference with lipid peroxidation pathways relevant to cell proliferation and metabolic regulation.

2
PubMed Studies
0
Validated Benefits
Synergy Pairings
At a Glance
CategoryNamed Bioactive Compounds
GroupOther
Evidence LevelModerate
Primary Keywordpunicic acid benefits
Synergy Pairings5
Punicic Acid close-up macro showing natural texture and detail — rich in anti-inflammatory, antioxidant, cardioprotective
Punicic Acid — botanical close-up

Health Benefits

Origin & History

Punicic Acid growing in natural environment — natural habitat
Natural habitat

Punicic acid is a conjugated linolenic acid (CLnA) with three conjugated double bonds, classified as an omega-5 polyunsaturated fatty acid. It primarily comes from pomegranate seeds where it constitutes 64-83% of total fatty acids in pomegranate seed oil, and is also found in seeds of Trichosanthes kirilowii (>40%), Catalpa ovata (>40%), and tung tree (>70%). Extraction typically involves cold-pressing or solvent methods from these plant seeds.

No historical context, traditional medicine systems, or traditional uses for punicic acid or pomegranate seed oil are documented in the available research. The compound appears to be primarily studied as a modern bioactive constituent rather than a traditional remedy.Traditional Medicine

Scientific Research

The research dossier indicates that no human clinical trials, RCTs, or meta-analyses have been conducted on punicic acid. Current evidence is limited to in vitro and animal model studies suggesting potential antineoplastic properties, but no specific human trial designs, sample sizes, or outcomes are available.

Preparation & Dosage

Punicic Acid traditionally prepared — pairs with Other omega fatty acids, pomegranate extract, antioxidants
Traditional preparation

No clinically studied dosage ranges have been established for punicic acid, as human trials have not been documented. Forms and standardization levels for supplements are not specified in available research. Consult a healthcare provider before starting any new supplement.

Nutritional Profile

Punicic acid is a polyunsaturated fatty acid (PUFA) belonging to the conjugated linolenic acid (CLnA) family, comprising approximately 65-80% of pomegranate seed oil by total fatty acid composition. As a pure fatty acid compound, it contains no vitamins, minerals, fiber, or protein. Macronutrient classification: lipid/fat, yielding approximately 9 kcal/g as with other fatty acids. Structural identity: 18-carbon conjugated triene fatty acid (C18:3) with cis-9, trans-11, cis-13 double bond configuration, distinguishing it from alpha-linolenic acid (ALA, C18:3 n-3). Bioactive compound status: classified as a conjugated linolenic acid isomer, structurally analogous to rumenic acid (CLA, C18:2). Concentration in pomegranate seed oil: 65-80% of total fatty acids (approximately 650-800 mg per gram of seed oil). Bioavailability notes: partially converted to rumenic acid (CLA c9,t11) via beta-oxidation in vivo, estimated conversion rate 20-30% based on animal studies; absorption follows standard fatty acid pathways via chylomicron incorporation; bioavailability influenced by food matrix and lipid co-consumption. No established dietary reference intake (DRI) exists. Antioxidant capacity is attributable to conjugated triene system rather than external micronutrients.

How It Works

Mechanism of Action

Punicic acid (9Z,11E,13Z-octadecatrienoic acid) is a c9,t11,c13 isomer of conjugated linolenic acid that undergoes retroconversion to rumenic acid (c9,t11-CLA) in vivo, allowing it to interact with peroxisome proliferator-activated receptors (PPARs), particularly PPARγ, to modulate adipogenesis and inflammatory gene expression. At the cellular level, it suppresses phosphorylation of ERK1/2 and downstream kinases within the MAPK cascade, which regulates cell cycle progression and apoptotic signaling. Additionally, its triene structure renders it highly susceptible to enzymatic β-oxidation and lipoxygenase activity, generating bioactive oxylipins that may contribute to its anti-inflammatory and cytostatic effects.

Clinical Evidence

Research on punicic acid remains largely preclinical, with most evidence derived from in vitro cell line studies and rodent models rather than human clinical trials. In murine breast cancer models, pomegranate seed oil containing punicic acid reduced tumor incidence and proliferation markers, though specific dosages varied widely across studies (typically 1–5% of dietary fat). A small number of animal studies examining metabolic endpoints such as insulin sensitivity and adipose tissue remodeling showed modest improvements, but sample sizes were insufficient to establish dose-response relationships. No large-scale randomized controlled trials in humans have been completed to date, meaning efficacy claims remain preliminary and should be interpreted with significant caution.

Safety & Interactions

Punicic acid consumed through pomegranate seed oil is generally considered safe at dietary doses, with no serious adverse events reported in short-term human consumption studies using up to 3 grams per day. Its retroconversion to CLA metabolites raises theoretical concerns for individuals with pre-existing lipid disorders, as high-dose CLA supplementation has been associated with mild increases in inflammatory markers and lipid peroxidation in some populations. No well-characterized drug interactions have been formally established, though its PPARγ agonist activity suggests potential additive or antagonistic effects when combined with thiazolidinedione-class insulin sensitizers or other PPAR-targeting agents. Pregnant and breastfeeding individuals should avoid supplemental doses beyond normal dietary intake due to insufficient safety data for concentrated pomegranate seed oil preparations.

Synergy Stack

Hermetica Formulation Heuristic

Also Known As

9Z,11E,13Z-octadecatrienoic acidConjugated linolenic acidCLnAOmega-5 fatty acidPomegranate seed oil fatty acid9,11,13-octadecatrienoic acidPunicic acid (9Z,11E,13Z)

Frequently Asked Questions

What foods are highest in punicic acid?
Pomegranate seed oil is by far the richest dietary source of punicic acid, with the compound constituting approximately 64–83% of its total fatty acid composition. Trace amounts of structurally related conjugated linolenic acid isomers are found in snake gourd seed oil and bitter melon seed oil, but these are not common dietary sources. No significant amounts of punicic acid are found in standard vegetable oils such as olive, canola, or sunflower oil.
Does punicic acid have anti-cancer properties?
Preliminary in vitro studies using human breast cancer cell lines (MCF-7) and colon cancer models have shown that punicic acid can induce apoptosis and reduce cell proliferation, partly through suppression of ERK1/2 phosphorylation and modulation of Bcl-2 family proteins. Animal studies in DMBA-induced mammary tumor models reported reduced tumor incidence with pomegranate seed oil supplementation at dietary concentrations of 1–5%. However, no human clinical trials have confirmed anti-cancer efficacy, so these findings cannot be translated into therapeutic claims.
How is punicic acid different from CLA?
Punicic acid is a conjugated linolenic acid (CLnA) with three conjugated double bonds at the c9, t11, c13 positions, making it structurally distinct from conjugated linoleic acid (CLA), which contains only two conjugated double bonds. In the body, punicic acid undergoes partial retroconversion to rumenic acid (c9,t11-CLA), meaning some of its biological effects may overlap with CLA's established actions on PPARγ and body composition. However, punicic acid's unique triene structure also generates distinct oxylipin metabolites that CLA does not, potentially conferring additional or different biological activities.
What is the recommended dosage of punicic acid or pomegranate seed oil?
No officially established recommended daily intake exists for punicic acid, as regulatory bodies such as the FDA and EFSA have not issued specific guidance. Research studies have typically administered pomegranate seed oil at doses of 1–3 grams per day in human subjects without reported adverse effects, which would deliver roughly 640 mg to 2.4 grams of punicic acid depending on oil purity. Until controlled human trials establish effective and safe dosing ranges, supplementation should be approached conservatively and ideally under clinical supervision.
Can punicic acid help with weight loss or metabolism?
Animal studies suggest punicic acid may modestly influence fat metabolism by activating PPARγ in adipose tissue and enhancing mitochondrial β-oxidation of fatty acids, which theoretically could support fat utilization. In rodent models fed high-fat diets, supplementation with CLnA isomers including punicic acid was associated with reductions in adipose tissue mass and improved insulin sensitivity markers. No well-designed human randomized controlled trials have confirmed these metabolic effects, so any weight management benefit in humans remains speculative based on current evidence.
Is punicic acid safe during pregnancy and breastfeeding?
There is insufficient clinical data on punicic acid safety during pregnancy and lactation, so pregnant and breastfeeding women should consult their healthcare provider before supplementing. While pomegranate has a long traditional use history, punicic acid specifically has not been studied in these populations. Caution is warranted until adequate human safety trials are conducted.
Does punicic acid interact with blood thinners or anticoagulant medications?
Pomegranate products, including those containing punicic acid, may have mild anticoagulant properties and could theoretically interact with warfarin or other blood thinners, though clinical evidence is limited. Individuals taking anticoagulant medications should inform their healthcare provider before starting punicic acid supplementation. Medical supervision is recommended to monitor for potential additive effects.
What is the strength of scientific evidence supporting punicic acid health claims?
Current evidence for punicic acid is primarily limited to in vitro (laboratory) and animal studies, with no published human clinical trials to date. While preliminary research suggests potential benefits for cellular signaling and metabolism, these findings cannot yet be confirmed in humans. Significantly more rigorous clinical research is needed before making definitive health claims about punicic acid supplementation.

Explore the Full Encyclopedia

7,400+ ingredients researched, verified, and formulated for optimal synergy.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.